Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 15 of 52 results for durvalumab

  1. Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)

    Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.

    Technology appraisal guidance
    Published
    10 January 2024
    View recommendations

    Sections for TA944

  2. Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA798)

    Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.

    Technology appraisal guidance
    Published
    22 June 2022
    View recommendations

    Sections for TA798

  3. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]

    Awaiting development [GID-TA11214] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

    In development [GID-TA10571] Expected publication date: 22 May 2025

    Technology appraisal guidance
    In development

  5. Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073]

    In development [GID-TA10959] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  6. Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) (TA662)

    NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZeneca withdrew its evidence submission.

    Technology appraisal guidance
    Published
    25 November 2020

    Sections for TA662

  7. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146

    Awaiting development [GID-TA11222] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    Awaiting development [GID-TA10748] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development [GID-TA11340] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  10. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development [GID-TA11161] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6404]

    Awaiting development [GID-TA11515] Expected publication date: 19 February 2025

    Technology appraisal guidance
    Awaiting development

  13. Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)

    Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

    Technology appraisal guidance
    Published
    11 September 2024

    Sections for TA1005

  14. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

    In development [GID-TA11405] Expected publication date: 18 September 2025

    Technology appraisal guidance
    In development

  15. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]

    In development [GID-TA10784] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development